WO2007033356B1 - Compositions and methods for green tea catechins for modification of detoxification enzymes - Google Patents
Compositions and methods for green tea catechins for modification of detoxification enzymesInfo
- Publication number
- WO2007033356B1 WO2007033356B1 PCT/US2006/035972 US2006035972W WO2007033356B1 WO 2007033356 B1 WO2007033356 B1 WO 2007033356B1 US 2006035972 W US2006035972 W US 2006035972W WO 2007033356 B1 WO2007033356 B1 WO 2007033356B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gst
- green tea
- activity
- person
- polyphenol composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
Abstract
Compositions and methods useful for increasing GST-pi expression and/or GST-pi activity in human penpheral blood cells by administering daily in an oral dosage a green tea polyphenol composition consisting of epigallocatechin gallate, epigallocathechin, epicatechin, epicatechin gallate, gallocatechin gallate and/or polyphenon E.
Claims
1. A method of increasing al least, one of a GST-π expression and a GST-π activity iii peripheral blood lymphocytes of a person comprising administering a green tea polyphenol composition to the person at a dosage effective to increase the at least one of the GST-π expression and the GST-π activity in peripheral blυυd lymphocytes and wherein the person is a person previously ascertained as having a low baseline GST-π activity in peripheral blood lymphocytes.
2. The method of claim 1 wherein the low baseline GST-π activity is characterized by a GST-π activity that is within a lower tortile of GST-π activities measured across a group of at least forty individuals.
3. The method of claim 1 wherein the green tea polyphenol composition comprises polyphenon E.
4. The method of claim 1 wherein the green tea polyphenol composition comprises a polyphenol selected from the group consisting of epigallocatcchin gallate, epigallocatcchin, epicatechin, epicatechin gallate, and gallocatechin gallalc.
5. The method of claim 1 wherein the green tea polyphenol composition is orally daily administered in an amount corresponding to an amount of total polyphenols in 8-16 cups of green tea.
6. The method of claim 1 wherein the low baseline GST-π activity is determined by at least one ofmcasuring GST-π quantity from a blood sample and measuring conversion of a marker substrate.
7. The method of claim 1 furlheτ comprising a step of providing information to the person that administration of the green tea polyphenol composition increases at least one of the GST-π expression and the GST-π activity.
8. Use of a green tea polyphenol composition in the manufacture of a medicament or nutraccutical preparation for increasing GST-π adivity in peripheral blood lymphocytes of a person having low baseline GST-π activity, wherein the person is a person previously ascertained as having a low baseline GST-π activity in peripheral blood lymphocytes, and wherein the medicament or nutraceutical preparation is formulated to allow administration of the green tea polyphenol composition to the person with the low baseline GST-π activity at a dosage effective to increase GST-π expression in peripheral blood lymphocytes.
9. Use of claim 8 wherein the medicament or nutraceutical preparation is formulated for oral administration.
K). Use of claim 8 wherein the step of administering comprises daily oral administration of the polyphenol composition in an amount corresponding to an amount of total polyphenols in 8-10 cups of green tea.
1 1. Use of claim 8 wherein green tea polyphenol composition comprises polyphcnon E.
12. Use of claim 8 wherein the green tea polyphenol composition comprises a polyphenol selected from the group consisting of epigallocatcchin gallate, epigallocalechin, epicatechin, epicalcchin gallate, and gallocatechin gallate.
13. A method of increasing potential efficacy of a treatment to reduce cancer risk in a person, comprising: ascertaining that the person has a low baseline GST-π activity in peripheral blood lymphocytes; and administering to the person with lhe low baseline GST-π activity the green tea polyphenol composition at a dosage effective to increase GST-π expression in peripheral blood lymphocytes; wherein administration increases potential efficacy of the treatment relative to a person having normal or high baseline GST-π activity in peripheral blood lymphocytes.
14. The method of claim 13 wherein the green tea polyphenol composition comprises polyphcnon E-
15. The method of claim 13 wherein the green tea polyphenol composition comprises at least one of cpigallocatechin gallate, cpigallocatechin, epicatechin, epicatechin gallate, and gallocatcchin gallate.
16. The method of claim 13 wherein the cancer risk is selected from the group of lung cancer risk, oral cancer risk, colon cancer risk, prostate cancer risk, and breasl cancer risk.
17. The method orclaim 13 wherein the step of ascertaining is performed by measuring GST-π quantity from a blood sample.
18. The method of claim 13 wherein the step of ascertaining is performed by measuring conversion of a marker substrate.
19. The method of claim 13 wherein the step of administering comprises oral administration.
20. The method of claim 1 y wherein the step of administering comprises daily oral administration ofthc polyphenol composition in an amount corresponding to an amount of total polyphenols in 8-16 cups of green tea.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71756105P | 2005-09-14 | 2005-09-14 | |
| US60/717,561 | 2005-09-14 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2007033356A2 WO2007033356A2 (en) | 2007-03-22 |
| WO2007033356A3 WO2007033356A3 (en) | 2007-10-04 |
| WO2007033356B1 true WO2007033356B1 (en) | 2007-12-06 |
Family
ID=37865597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2006/035972 WO2007033356A2 (en) | 2005-09-14 | 2006-09-13 | Compositions and methods for green tea catechins for modification of detoxification enzymes |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2007033356A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014088520A1 (en) * | 2012-12-03 | 2014-06-12 | Eraslan Mustafa | Usage of fig fruit extract and olive leaf extract combinations together with green tea and grape seed extracts |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6646013B1 (en) * | 1999-06-15 | 2003-11-11 | Nutri-Logics | Nutrient formulations for disease reduction |
| CA2471932A1 (en) * | 2002-01-11 | 2003-07-17 | Matthias Rath | A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer |
-
2006
- 2006-09-13 WO PCT/US2006/035972 patent/WO2007033356A2/en active Search and Examination
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007033356A2 (en) | 2007-03-22 |
| WO2007033356A3 (en) | 2007-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xie et al. | Ganoderma lucidum extract inhibits proliferation of SW 480 human colorectal cancer cells | |
| Demeule et al. | Green tea catechins as novel antitumor and antiangiogenic compounds | |
| Fassina et al. | Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate | |
| Khan et al. | Tea polyphenols for health promotion | |
| JP6310971B2 (en) | Methods and compositions for treating HIV-related diarrhea | |
| Dwyer et al. | Tea and flavonoids: where we are, where to go next | |
| JP6159084B2 (en) | Composition containing berberine or an analogue thereof for treating skin diseases associated with rosacea or blush | |
| Dou | Tea in health and disease | |
| CN102204874B (en) | Anti-halitosis toothpaste containing natural drug compound components | |
| AU2007249801A1 (en) | Food compositions and methods of treating periodontal disease | |
| WO2006013420B1 (en) | Mixture of catechins or rather polyphenols extracted from chinese green tea or other vegetables for the prevention of prostate cancer and for the treatment of prostate hypertrophy (bph) | |
| US7192612B2 (en) | Compositions and methods based on synergies between capsicum extracts and tea catechins for prevention and treatment of cancer | |
| WO2010057034A1 (en) | Compositions and methods for alleviating hyposalivation and for providing oral comfort | |
| WO2007033356B1 (en) | Compositions and methods for green tea catechins for modification of detoxification enzymes | |
| SE0000698D0 (en) | Use of a composition | |
| CN101411781A (en) | Use of pu'er tea in preparing medicament for treating or preventing diabetes | |
| Zhou et al. | A local dark tea–Liubao tea–extract exhibits remarkable performance in oral tissue regeneration, inflammation relief and oral microbiota reconstruction | |
| Abdelkawy et al. | Pharmacokinetics interaction of dapoxetine with different doses of green tea extract in male healthy volunteers using midazolam as CYP3A4 enzyme probe | |
| Roomi et al. | Suppression of growth and hepatic metastasis of murine B16FO melanoma cells by a novel nutrient mixture | |
| Palwankar et al. | Green tea a magical herbal therapy | |
| JPWO2019131274A1 (en) | Method for producing fermented product derived from green tea extract and fermented koji product derived from green tea extract | |
| KR20070019395A (en) | Composition for anti-obesity health food in the form of a tablet containing green tea extract | |
| EP1874354A1 (en) | Nutrient composition comprising green tea polyphenols for treating osteosarcoma | |
| CN102526033B (en) | Composition prepared from epigallocatechin gallate and mitomycin C and used for suppressing tumor cell proliferation | |
| Wang et al. | Balancing adipocyte production and lipid metabolism to treat obesity-induced diabetes with a novel proteoglycan from Ganoderma lucidum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 06824969 Country of ref document: EP Kind code of ref document: A2 |
|
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) |